Clinical trials: Generalised Lipodystrophy
- Condition Generalised Lipodystrophy
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Generalized Lipodystrophy
Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy
The primary objectives of the study are to estimate the effects of REGN4461 on glycemic parameters in the subset of patients with elevated baseline hemoglobin A1c levels (HbA1c ≥7%) and to estimate the effects of REGN4461 on…
- Trial name
- NCT04159415
- Testing
- Low-Dose REGN4461, High-dose REGN4461
- Where
- 8 sites in United States, Peru and 2 more
- Volunteers
- 16 people
- Sponsor
- Regeneron Pharmaceuticals
Generalized Lipodystrophy
Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy
MYALEPT™ (metreleptin) has been approved as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (MYALEPT Prescribing…
- Trial name
- NCT04026178
- Testing
- Metreleptin
- Where
- 8 sites in United States
- Volunteers
- 11 people
- Sponsor
- Aegerion Pharmaceuticals, Inc.